DIRECT BIOLOGICS Trademark
DIRECT BIOLOGICS is a USPTO trademark filed by Direct Biologics, LLC. Status: Pending.
Trademark Facts
| Mark | DIRECT BIOLOGICS |
|---|---|
| Serial Number | 99361536 |
| Status | Pending |
| Filing Date | 2025-08-27 |
| Mark Type | Word |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals), 044 (Medical Services) |
| Owner | Direct Biologics, LLC |
| Attorney of Record | Aaron D. Hendelman |
| Prosecution Events | 11 |
| Latest Event | CNSA on 2026-05-08 |
Goods & Services
Class 001: Exosomes for use in the manufacture of cosmetics and pharmaceuticals; Class 005: Pharmaceutical and therapeutic preparations for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; pharmaceutical and therapeutic preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of inflammation, inflammation-derived diseases, acute respiratory disease syndrome (ARDS), Crohn’s disease, perianal fistulizing disease, colitis, pulmonary fibrosis, hair loss, alopecia, psoriasis, ulcers, joint pain, discogenic pain, lumbar and cervical radiculopathy, osteoarthritis, COVID-19, hip labral tears, traumatic brain injury, amyotrophic lateral sclerosis (ALS), chronic regional pain syndrome (CRPS), facial nerve damage, Bell’s Palsey, Ehler’s Danlos Disease, wound care, and skin damage; regenerative medicine, namely, pharmaceuticals and therapeutics for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system-related diseases and disorders; Class 044: Gene therapy; cell therapy; services in the field of regenerative medicine; diagnosing the need for, and administering, regenerative medicine; regenerative medicine services
Recent Prosecution Activity
| Date | Document | Type |
|---|---|---|
| 2026-03-23 | Response to Office Action | ROA |
| 2026-01-21 | Public Note | PNR |
| 2026-01-21 | Non-Final Action | NFIN |
| 2026-01-21 | XSearch Search Summary | XSS |
| 2025-08-27 | Application | APP |
USPTO Refusals on Record
- merely_descriptive